SI-BONE, Inc.
SIBN- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001459839
In the last 90 days, SI-BONE, Inc. insiders filed 0 open-market purchases and 18 sales; 167 institutions reported holding it in 13F filings for Q2 2026, worth $773.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:15 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $18.9M (9.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $200.9M | $167.2M | $138.9M | $106.4M | $90.2M |
| Cost of revenue | $41.0M | $35.1M | $29.5M | $15.7M | $10.4M |
| Gross profit | $159.9M | $132.1M | $109.4M | $90.7M | $79.7M |
| Operating expenses | $182.2M | $167.4M | $156.4M | $150.3M | $131.4M |
| Research and development | $17.4M | $16.6M | $15.0M | $13.6M | $12.4M |
| Selling, general and administrative | $40.5M | $33.8M | $31.1M | $29.0M | $25.1M |
| Operating income | -$22.3M | -$35.2M | -$46.9M | -$59.6M | -$51.7M |
| Interest expense | – | – | $3.46M | $2.82M | $5.37M |
| Income tax | $0 | $0 | $0 | $0 | – |
| Net income | -$18.9M | -$30.9M | -$43.3M | -$61.3M | -$56.6M |
| EPS, basic | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 |
| EPS, diluted | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 |
| Weighted shares, basic | 43.0M | 41.5M | 38.4M | 34.2M | 33.1M |
| Weighted shares, diluted | 43.0M | 41.5M | 38.4M | 34.2M | 33.1M |
| Margins and growth | |||||
| Gross margin | 79.6% | 79.0% | 78.8% | 85.2% | 88.4% |
| Operating margin | -11.1% | -21.1% | -33.8% | -56.0% | -57.3% |
| Net margin | -9.4% | -18.5% | -31.2% | -57.6% | -62.8% |
| Revenue growth, year over year | +20.2% | +20.4% | +30.5% | +18.0% | +22.8% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $42.2M | $34.9M | $33.3M | $20.7M | $63.4M |
| Accounts receivable | $29.9M | $27.5M | $22.0M | $20.7M | $14.2M |
| Inventory | $33.9M | $27.1M | $20.2M | $17.3M | $11.5M |
| Total current assets | $216.1M | $207.8M | $211.4M | $137.6M | $175.9M |
| Property, plant and equipment | $21.3M | $20.4M | $16.0M | $15.6M | $8.99M |
| Total assets | $238.6M | $230.4M | $230.4M | $157.6M | $190.5M |
| Accounts payable | $4.63M | $6.49M | $4.59M | $6.28M | $3.20M |
| Total current liabilities | $25.3M | $27.1M | $23.5M | $21.2M | $16.9M |
| Long-term debt | $35.6M | $35.5M | $36.1M | $35.2M | $35.0M |
| Total liabilities | $61.0M | $63.5M | $61.0M | $59.3M | $56.1M |
| Shareholders' equity | $177.5M | $167.0M | $169.4M | $98.3M | $134.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 12, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | -$675.0K | -$12.4M | -$18.7M | -$41.7M | -$39.5M |
| Capital expenditures | $8.41M | $10.5M | $7.80M | $9.51M | $6.39M |
| Free cash flow | -$9.09M | -$22.9M | -$26.5M | -$51.2M | -$45.9M |
| Depreciation and amortization | $5.77M | $4.38M | $5.43M | $3.45M | $2.09M |
| Stock-based compensation | $25.5M | $25.9M | $24.1M | $23.1M | $16.9M |
| Investing cash flow | $4.16M | $12.6M | -$59.8M | -$2.81M | $51.6M |
| Financing cash flow | $3.38M | $1.96M | $90.9M | $2.20M | -$1.71M |
| Net change in cash | $7.29M | $1.68M | $12.6M | -$42.7M | $9.84M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 12.7% | 15.5% | 17.3% | 21.7% | 18.7% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.